共 362 条
[1]
Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[2]
Miller KD(2018)Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study JAMA Oncol 4 1553-1568
[3]
Jemal A(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1512
[4]
Fitzmaurice C(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-1520
[5]
Akinyemiju TF(2016)Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Lancet 387 1163-1177
[6]
Al Lami FH(2015)Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer N Engl J Med 373 737-746
[7]
Alam T(2012)Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer World J Surg Oncol 10 1-e122
[8]
Alizadeh-Navaei R(2019)Radical prostatectomy with and without Neoadjuvant Chemohormonal pretreatment for high-risk localized prostate Cancer: a comparative propensity score matched analysis Clin Genitourin Cancer 17 e113-388
[9]
Allen C(2014)ERG induces taxane resistance in castration-resistant prostate cancer Nat Commun 5 5548-380
[10]
Alsharif U(2012)Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells Cancer Cell 22 373-2581